Alemtuzumab (Campath-1H) for treatment of refractory polymyositis.
Ben
B
Thompson
Paul
P
Corris
James A L
JA
Miller
Robert G
RG
Cooper
John P
JP
Halsey
John D
JD
Isaacs
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D018655:Lymphocyte Count; D008875:Middle Aged; D017285:Polymyositis / Q000188:drug therapy*; D017211:Treatment Failure
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D018501:Antirheumatic Agents; D000074323:Alemtuzumab